Founded by a team of Imperial College London alumni in 2016, Circadia Health is on a mission to develop an AI-driven platform to transform respiratory, sleep, and neurological care. The company already raised over $1.5M in VC funding, from Village Global (the venture firm backed by Mark Zuckerberg and Bill Gates), SOSV Ventures, CentreGold, and Particular Ventures.
A breakthrough in remote monitoring
The Circadia C100 is a breakthrough device that remotely monitors respiration. The C100 works up to four feet away from the patient, hence ensuring the front line workers’ safety. The device uses technologies initially developed for radars. It emits electromagnetic waves in the microwave frequency band to track respiration.
Relying on signal processing and machine learning algorithms, the continuous analysis of the patient respiration pattern allows for early detection of the breathing pattern deterioration. During the COVID times we live in, the technology can alert physicians in real-time and support the clinical decision process.
FDA Cleared and ready for COVID-19 patients
In June 2020, the London-based company received FDA 510(k) clearance for its C100 System. This certification opens the doors for the use of C100 in Hospitals, care homes, and even at-home telehealth. To reduce the risk of exposure to COVID-19 of the front-line workers, the company pledged $3 million in providing 2,000 respiratory monitors to hospitals. The Circadia’s C100 relies on AI-powered algorithms to track respiratory patterns and identify potential worsening of lung function.
According to the co-Founder and CEO, Fares Siddiqui, “breathlessness,” which is one of the early signs of respiratory distress in COVID-19 patients. “can be picked up and enable timely interventions effectively.”
The proprietary radar Signal Analysis Technology (rSAT®) and AI-powered algorithms can also monitor motion, presence, and sleep quality. The system’s versatility allows its use both from hospitals and even at home for patients experiencing episodes of bradypnea, tachypnea, or COPD exacerbation.
Remote monitoring of the patients at home or in the hospitals is a $12 billion market with clear support both from the patients and the healthcare workers. In a study conducted by Sony Health, 90p100 of the patients said they could better manage their condition with a remote monitoring solution. During the COVID-19 outbreak, 61p100 of the respondents mentioned that they would feel safer if their doctor recommended using a remote monitoring solution.
A complete remote monitoring solution
Circadia Health offers a complete cloud-based remote monitoring solution. According to Dr. Guy Leschziner, chief medical officer for Circadia, the company is “building a ubiquitous data-driven platform…to develop proprietary early warning risk scores for various medical conditions.”
The company’s business model is to provide the device free of charge and charge a monthly fee of $123 per patient, per month, under billable CPT codes. The platform is HIPAA compliant, ISO 13485:2016, and Class II Medical Device: FDA 510(k) cleared.
More than just detecting the breathing pattern, the technology, and proprietary algorithms also predict sleep stages. The accuracy is close to the recordings based on Polysomnography and exceeds the consumer sleep tracking devices.
Circadia is on its way to revolutionize the respiratory remote monitoring landscape and we look forward to follow their bright future.
